Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.
Piramal Pharma anticipates a significant turnaround in financial year 2026-27 (FY27), projecting early-to-mid teens revenue expansion and a sharp improvement in profitability, driven by improved business momentum, new product acquisitions, and structural tailwinds.
The ongoing West Asia conflict is expected to severely impact the supply of affordable housing in India, as rising input costs further erode already thin developer margins. Fluctuations in crude oil and gas prices, coupled with higher freight costs, are driving up prices of essential construction materials like cement and steel, making new projects increasingly unviable for developers.
India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.
Dr Reddy's Laboratories has received approval from Health Canada to sell a generic version of the diabetes drug semaglutide, making it the first company to get market authorisation for a generic semaglutide injection in Canada and the first in a G7 country.
India's electric motorcycle market is experiencing significant growth, with a 28 per cent year-on-year increase in volumes, as new product launches and improved total cost of ownership attract a broader base of riders beyond early adopters.
The Federation of Indian Export Organisations (FIEO) has appealed to the Reserve Bank of India (RBI) for liquidity support to Indian exporters, citing a significant increase in freight costs and extended payment cycles due to the ongoing West Asia conflict.
Young adults show alarming NCD trends, with high rates of obesity, prediabetes, and abnormal cholesterol levels.
Indian realty developers are contemplating price increases for ongoing and upcoming projects to offset margin pressures caused by rising input costs and supply chain disruptions, exacerbated by the West Asia conflict. Input and labour costs have surged by 5-12%, directly impacting developer margins, especially for under-construction projects.
BMW India has outpaced rival Mercedes-Benz India in luxury car registrations for the first quarter of calendar year 2026, driven by new product launches and a growing electric vehicle segment, even as the overall luxury car market remains largely flat.
Ongoing geopolitical tensions in West Asia have slowed deal momentum in Dubai's luxury residential market, but Indian high-net-worth individuals (HNIs) are not exiting their marquee assets, with any 'discounted' resale deals attributed to investor liquidity stress rather than geopolitical flight.
The inauguration of Noida International Airport (NIA) is set to significantly increase property values in micro-markets along the Yamuna Expressway, with projections indicating a 28 per cent rise for plots and 22 per cent for apartments over the next two years, according to Colliers.
Ola Electric Mobility Ltd is redirecting 575 crore from its initial public offering (IPO) proceeds, originally earmarked for research and product development, towards debt repayment and organic growth initiatives, signalling mounting pressure on the electric-vehicle maker.
Inspections conducted across 49 entities including pharmacies, wholesalers, and clinics to detect violations and misleading marketing practices.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
Escalating geopolitical tensions in West Asia are prompting investors with exposure to Dubai's real estate market to reassess their portfolios. And, in this rejig, India is emerging as a stable destination for capital investment and long-term growth.
While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.
The outreach comes amid a drop in Indian student enrolments in management programmes at American universities last year, following changes to US student visa policies.
'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'
The government has intensified its Study in India programme and is working closely with universities and states to achieve this goal.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances